de novo design of multitarget ligands (MultiTarget Pharmaceuticals)
90
Structured Review
MultiTarget Pharmaceuticals
de novo design of multitarget ligands
De Novo Design Of Multitarget Ligands, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/de+novo+design+of+multitarget+ligands/de+novo+design+of+multitarget+ligands/pm38261411-460-20-20
Average 90 stars, based on 1 article reviews
De Novo Design Of Multitarget Ligands, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/de+novo+design+of+multitarget+ligands/de+novo+design+of+multitarget+ligands/pm38261411-460-20-20
Average 90 stars, based on 1 article reviews
de novo design of multitarget ligands - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit. Article Snippet: In this work, a series of multitargeting histone deacetylase (HDAC) inhibitors capable of regulating the signal transduction between RAS protein and downstream effectors were obtained by introducing a zinc-ion-binding group into the framework of rigosertib via different linkers.. Among them, two representative compounds, XSJ-7 and XSJ-10, not only showed stronger antiproliferative activity against many types of cancer cells including solid tumor cells but also presented more potent inhibition on different subtypes of HDAC than suberoylanilide hydroxamic acid (SAHA).. Significantly, XSJ-10 presented moderate pharmacokinetic behaviors and showed stronger antitumor activity than oxaliplatin, SAHA, and rigosertib in the HT-29 xenograft mouse models without significant systemic toxicity. Article Title: Demonstration of AutoDock as an Educational Tool for Drug Discovery Article Snippet: Model. 2014, 54 (3), 693−704. (3) Shang, E.; Yuan, Y.; Chen, X.; Liu, Y.; Pei, J.; Lai, Article Title: Diverse ways of perturbing the human arachidonic acid metabolic network to control inflammation. Article Snippet: CONSPECTUS: Inflammation and other common disorders including diabetes, cardiovascular disease, and cancer are often the result of several molecular abnormalities and are not likely to be resolved by a traditional single-target drug discovery approach.. Though inflammation is a normal bodily reaction, uncontrolled and misdirected inflammation can cause inflammatory diseases such as rheumatoid arthritis and asthma.. Nonsteroidal anti-inflammatory drugs including aspirin, ibuprofen, naproxen, or celecoxib are commonly used to relieve aches and pains, but often these drugs have undesirable and sometimes even fatal side effects. |